Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
about
DangER: protein ovERload. Targeting protein degradation to treat myelomaIncorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like SitesThe immunoproteasome and viral infection: a complex regulator of inflammationProfound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodesMolecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo.Subunit specific inhibitors of proteasomes and their potential for immunomodulationThe proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.A novel proteasome inhibitor NPI-0052 as an anticancer therapy.Application of activity-based probes to the study of enzymes involved in cancer progression.Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasomeTargeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitorsA phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.Inhibitors of the immunoproteasome: current status and future directionsMyeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.Proteasome inhibitors: an expanding army attacking a unique target.A bright approach to the immunoproteasome: development of LMP2/β1i-specific imaging probes.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Activity-based probes for the multicatalytic proteasome.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sitesLMP2-specific inhibitors: chemical genetic tools for proteasome biology.Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.A panel of subunit-selective activity-based proteasome probesAn Overview of Bortezomib-Induced NeurotoxicityPR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
P2860
Q26825417-04887BBB-EC76-487E-A219-FCAA260E7F16Q27675903-AD8392D4-81A4-47C8-A5E0-1B75AC62772EQ27694656-252F5DBB-599F-4015-8111-33B3DA77DC18Q28542496-355A95DC-2088-4760-B771-2AE3CE7A9DB6Q34608271-761D7F65-B690-4292-974F-1006AF4C9395Q34788381-6F3CFFFD-A773-4449-B3B3-50FEA6FD12B0Q35009005-0B5893B1-31EE-43D0-9781-814033C5255AQ35107469-B573AD35-4FD8-4BA6-88CB-AF128931CF6BQ35408665-0D37E413-B451-402B-982F-6A4BF774105EQ35842817-44CCA699-F076-4740-9F6E-7323C7129CD1Q35856827-F6F8CFCC-2A03-48A9-993E-6C9E219C9970Q36042649-DE5B507D-CA4F-44C8-BB68-C7602A641D39Q36372909-48795211-332D-4E90-A1C2-ECF5EC6CB8DEQ36407085-51535633-3D23-4015-B12D-222D58C246CCQ36626591-5C0CDC26-F6E2-4E40-AC0E-1337F85D35E5Q36775132-5C22FCC6-DCB1-4331-93AE-56350BC51986Q36782542-0A8C75E3-C9B4-4E3E-BC08-A2EAF6EAF245Q37187543-457076E5-0221-4760-8AF3-C1B78C724A38Q37199819-F64F198B-0C03-438C-AC40-ECE990DCBD78Q37292307-40226657-1AFE-4B73-A59E-02F26FC892C2Q37365560-F58A3056-4417-44A4-B773-15AA3DF4E44AQ37550051-B532BB69-A632-4B7F-ABB4-7FA1FD6BC8C1Q37979388-CFA77572-9805-4A9A-A733-F481C000B95AQ38712612-D7B5155C-65AB-4180-9A70-3BCBAFD13554Q39034873-C54654DB-C134-4003-895A-0919DCFD57EDQ39096761-2A9BF405-5264-4E0E-9003-11CB52270AC1Q39174431-EB33C95E-7038-4F3E-AE7D-341190715913Q39537071-EDE88D98-A101-402F-9F73-30E1E00562BAQ39753695-6DD0C646-927D-4B98-9B16-B719C3CF0328Q40140606-AB2D474F-8ABE-4EA9-AFBE-A6571B9D2C87Q40223062-9571FEAE-DF08-4585-A6B2-4E01099BBCB6Q41607725-05448D84-7D95-4C8F-B9BD-E696B2ADAF3AQ42170718-224EB627-2694-4A75-B9B3-80C8E3B56AE6Q42361419-645124DB-8C4B-4C93-8EDC-C93C4B7DF795Q42821645-C7846A19-EB3D-494E-ADD1-5A3F98CEF32BQ47102326-BF743205-5AE9-4917-AC67-1641C289748BQ48117457-F3C98D37-9742-4DE0-BDA6-6B8C0AD0FAA2
P2860
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effects of PS-341 on the activ ...... mes in multiple myeloma cells.
@en
type
label
Effects of PS-341 on the activ ...... mes in multiple myeloma cells.
@en
prefLabel
Effects of PS-341 on the activ ...... mes in multiple myeloma cells.
@en
P2093
P1433
P1476
Effects of PS-341 on the activ ...... mes in multiple myeloma cells.
@en
P2093
Hidde L Ploegh
Kenneth C Anderson
Paul J Galardy
Reshma Shringarpure
Richard LeBlanc
Teru Hideshima
P304
P356
10.1158/0008-5472.CAN-05-0506
P407
P577
2005-09-01T00:00:00Z